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 Prescription Monitoring Program Update
As of June 30, 2012, 3,352 prescribers and 1,308 pharmacists 
have registered to use the Iowa prescription monitoring program 
(PMP). Between January 1, 2012 and June 30, 2012, prescribers 
submitted 50,257 requests for data. During the same period, 
pharmacists submitted 4,955 requests. If this trend continues 
during the remainder of 2012, the number of requests from pre-
scribers will increase 41% from 2011 and the number of requests 
from pharmacists will increase 21% from 2011. The program is 
continuing to reduce the incidence of patients who utilize mul-
tiple pharmacies and multiple prescribers to obtain controlled 
substances. The number of patients who received Schedule II, 
III, and IV controlled substances from fi ve or more prescribers 
or pharmacies decreased 53% between 2009 and 2011, from 
3,293 incidents in 2009 to 1,769 in 2011. This downward trend is 
continuing in 2012. Between January 1, 2012 and June 30, 2012, 
830 incidents were reported. 
The following changes have been made to the Iowa PMP:
 ♦ Effective July 1, 2012, prescribers and pharmacists may 
authorize agents to register for the program and access and 
retrieve PMP data on their behalf. A prescriber or pharmacist 
may authorize no more than three agents. Please visit the fol-
lowing Web site for more information: www.state.ia.us/ibpe/
pmp/pmp_info.html.
 ♦ Beginning January 1, 2013, pharmacies will be required to 
submit controlled substance dispensing information to the 
PMP on not-less-than a weekly basis.
 ♦ Nonresident (out-of-state) pharmacies licensed in Iowa will be 
required to report to the Iowa PMP beginning January 1, 2013.
CPE Monitor
The Iowa Board of Pharmacy encourages pharmacists and 
pharmacy technicians to obtain their National Association of 
Boards of Pharmacy® (NABP®) e-Profi le ID by setting up their 
e-Profi le and registering for CPE MonitorTM. Even if a licensee has 
already created his or her e-Profi le, completion of CPE Monitor 
registration is necessary in order to fully activate his or her e-
Profi le ID and enable the CPE activity monitoring and tracking 
capability. Soon all Accreditation Council for Pharmacy Education 
(ACPE)-accredited CPE providers will require licensees to submit 
their NABP e-Profi le ID and date of birth (MMDD) in order to 
obtain credit for CPE activities. Currently, more than 90 ACPE-
accredited providers are actively transmitting CPE data through 
CPE Monitor. Pharmacists and pharmacy technicians may visit 
www.MyCPEmonitor.net to set up their e-Profi le, register for CPE 
Monitor, and obtain their e-Profi le ID.
Pharmacist Continuing Professional 
Development 
Continuing professional development (CPD) is a self-directed, 
practitioner-centered, outcomes-based model that is designed 
to meet the learning needs of the individual pharmacist. This 
approach has been implemented using a variety of models and 
regulatory frameworks in various health professions and countries 
and is now being explored by the Iowa Board of Pharmacy. The 
Board and the Iowa Pharmacy Association have recently formed a 
CPD Task Force to look at using CPD as a means for pharmacist re-
licensure. The task force has two goals: (1) to create a mechanism 
for pharmacists to seek re-licensure by means of CPD in lieu of, or 
in addition to, traditional continuing education (CE) requirements; 
and (2) to develop components of a CPD portfolio and a systematic 
rubric to evaluate CPD as a method of re-licensure for practicing 
pharmacists. From July 2012 through June 2013, a select group of 
Iowa pharmacists will adopt CPD as a method for documenting 
CE and other learning activities. The selected pharmacists will 
receive education regarding CPD; guidance on using the portfolio 
to refl ect, plan, evaluate, and record their learning activities; and 
information about the evaluation rubric that will be used to assess 
their portfolios. Due to the timeline of this project, the evaluation 
will occur after one year, but the project will continue for the entire 
two-year license renewal period. An interim progress report of 
the CPD Task Force will be presented to the Board in July 2013. 
Currently, there are approximately four states evaluating the use 
of CPD. In addition, ACPE has created a CPD Task Force, which 
closely monitors the advancement of CPD nationally. 
Board Licensing and Registration Statistics 
– Summer 2012
 ♦ Iowa-licensed pharmacists: 5,802 (3,363 residing in Iowa)
 ♦ Registered, nationally certifi ed pharmacy technicians: 4,129
 ♦ Registered, uncertifi ed pharmacy technicians (including 
trainees): 1,213
Continued on page 4
scriptions. They report that when they call the pharmacy to complain 
about the missing number of tablets or capsules the pharmacy staff 
insists the proper quantity was dispensed. ISMP also receives reports 
from pharmacists reporting this same situation. The concern is that 
pharmacy personnel may be diverting the medication, the patient may 
be seeking more medication than what was prescribed, or some of 
the medication may be taken by someone else in the patient’s home.
In the US, we dispense almost all oral solid drugs as loose tablets 
or capsules in a plastic vial that is labeled for the patient. This manner 
of dispensing makes diversion of a few tablets or capsules relatively 
easy. However, in many other countries, unit-dose and unit-of-use 
packaging is widely used.
It seems to reason that if unit-of-use, manufacturer-sealed contain-
ers or individual unit-dose packages of medications were used in the 
US for these drugs, diversion and/or speculation of diversion could 
be reduced. Manufacturers could produce unit-dose or unit-of-use 
packages, in numbered strips for ease of inventory and dispensing. 
Patients could be asked to sign for and agree to the amount dispensed 
at the point-of-sale. The numbered packaging would also help patients 
at home know if they had taken their medication or possibly alert 
them to diversion within their home. Of course, prescribers would 
need to prescribe quantities available in patient compliance packs or 
in multiples of that packaging, and insurance companies would have 
to pay for this specialized packaging.
Unit-of-use packs would provide other safety benefits. For ex-
ample, patients would be able to verify the drug name on the label for 
each dose, which would add a redundancy in checking the pharmacy 
label to what was actually dispensed. Also, the manufacturer could 
print and attach the patient information sheet and/or medication 
guide to the package the patient receives, eliminating extra work in 
the pharmacy to print and supply these mandated education sheets 
to the patient.
It is evident that further steps must be taken to reduce and minimize 
abuse of prescription drugs. It is critical that education be provided 
to patients, caregivers, and health care providers to increase aware-
ness about the dangers of prescription drug abuse and about ways to 
appropriately prescribe, dispense, store, and dispose of prescription 
medications. Development and deployment of consumer-friendly and 
environmentally responsible prescription drug disposal programs may 
also help to limit diversion (as well as reduce the risk of accidental 
ingestion) of drugs by family members and friends. FDA must con-
tinue its efforts to require new concepts for risk evaluation and miti-
gation strategies and provider education for opioid drugs. For more 
information on understanding prescription drug abuse, and to request 
Parents’ Guide to Understanding Prescription Drug Abuse brochures 
for distribution to your patients, visit www.SafeguardMyMeds.org.
Counterfeit Vicodin ES Sold Via Rogue Internet 
Drug Outlet, Abbott Reports 
In March 2012, Abbott warned consumers and health care provid-
ers about counterfeit Vicodin® ES purchased via the Internet. Abbott 
reports that the counterfeit product drug and package do not match 
that of Abbott’s FDA-approved Vicodin ES (hydrocodone bitartrate 
and acetaminophen). Descriptions and images of the counterfeit 
product and authentic Vicodin ES are shown in a consumer alert 
posted on the Abbott Web site at www.abbott.com/vicodin-consumer- 
alert.htm. Abbott advises that anyone who has the counterfeit ver-
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FDA Warned Medical Practices About 
Counterfeits in US and Risks to Patients 
In April 2012, Food and Drug Administration (FDA) sent letters to 
medical practices in several states requesting that they stop administer-
ing drugs purchased from any foreign or unlicensed source. FDA’s 
letters were sent in response to the discovery that the medical practices 
purchased medications from foreign or unlicensed suppliers that sold 
illegal prescription medications. FDA has advised that these medical 
practices are putting patients at risk of exposure to medications that 
may be counterfeit, contaminated, improperly stored and transported, 
ineffective, and dangerous. 
In an FDA statement, the agency urges the health care community 
“to examine their purchasing practices to ensure that they buy directly 
from the manufacturer or from licensed wholesale drug distributors 
in the United States.” Further, FDA reminds health care providers, 
pharmacies, and wholesalers/distributors that they are valuable part-
ners in protecting consumers from the threat of unsafe or ineffective 
products that may be stolen, counterfeit, contaminated, or improperly 
stored and transported. FDA advises that the receipt of suspicious or 
unsolicited offers from unknown suppliers should be questioned, and 
extra caution should be taken when considering such offers. 
FDA notes that the “Verify Wholesale Drug Distributor Licenses” 
FDA Web page, available at www.fda.gov/Drugs/DrugSafety/ 
DrugIntegrityandSupplyChainSecurity/ucm281446.htm, may be used 
to verify that a wholesale drug distributor is licensed in the state(s) 
where it is conducting business.
The FDA warning letters were sent following two incidences of 
counterfeit injectable cancer drugs found in US medical practices, 
one in February 2012, involving counterfeit Avastin® 400 mg/16 mL, 
and another in April 2012, involving a counterfeit version of Roche’s 
Altuzan® 400 mg/16 ml (bevacizumab). 
More information and a list of the medical practices that were 
sent warning letters are available on the FDA Web site at www 
.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/
ucm299920.htm.
Rethink the Vial
This column was prepared by the Insti-
tute for Safe Medication Practices (ISMP). 
ISMP is an independent nonprofit agency 
that analyzes medication errors, near miss-
es, and potentially hazardous conditions as 
reported by pharmacists and other practitioners. ISMP then makes 
appropriate contacts with companies and regulators, gathers expert 
opinion about prevention measures, and publishes its recommenda-
tions. To read about the risk reduction strategies that you can put into 
practice today, subscribe to ISMP Medication Safety Alert!® Com-
munity/Ambulatory Care Edition by visiting www.ismp.org. ISMP 
is a federally certified patient safety organization, providing legal 
protection and confidentiality for submitted patient safety data and 
error reports. ISMP is also an FDA MedWatch partner. Call 1-800/
FAIL-SAF(E) to report medication errors to the ISMP Medication 
Errors Reporting Program or report online at www.ismp.org. ISMP 
address: 200 Lakeside Dr, Suite 200, Horsham, PA 19044. Phone: 
215/947-7797. E-mail: ismpinfo@ismp.org.
Recently, ISMP has been receiving many reports from consumers 
who report the pharmacy “shorted them” on a variety of opioid pre-
Page 3
National Pharmacy Compliance News
(Applicability of the contents of articles in the National Pharmacy Compliance News to a particular state or jurisdiction should not be assumed 
and can only be ascertained by examining the law of such state or jurisdiction.)
sion should stop taking the product. Further, consumers who suspect 
a product to be counterfeit or have questions about the legitimacy of 
Vicodin ES are encouraged to make a report to FDA Office of Criminal 
Investigations (OCI) by calling 800/551-3989 or by completing the 
online form on the OCI Web site at www.accessdata.fda.gov/scripts/
email/oc/oci/contact.cfm. 
PSM LEADER’s Guide Offers Tips for Protecting 
Patients from Counterfeits 
The Partnership for Safe Medicines (PSM) released a guide to 
assist health care providers in protecting patients from counterfeit 
drugs and recognizing the signs that may indicate use of counterfeits. 
Three versions of the LEADER’s Guide – including one for nurses, 
one for doctors, and another specific to pharmacists – are available 
for download from the PSM Web site at www.safemedicines.org/
resources-for-healthcare-professionals.html. Each guide provides 
tips specific to these health care provider roles and includes guidance 
for safe sourcing of medications, evaluating suspect medications, 
educating patients about counterfeit drugs and the risks of ordering 
drugs online, and reporting suspected counterfeit drugs. 
FDA Urges Providers to Help Prevent Children’s 
Accidental Exposure to Fentanyl Patches 
FDA issued a safety alert reminding patients, caregivers, and health 
care providers to appropriately store, use, and dispose of fentanyl 
patches to prevent children’s accidental exposure to the medication, 
which is potentially life-threatening. FDA recently evaluated a series 
of 26 cases of pediatric accidental exposures to fentanyl patches 
reported over the past 15 years, and determined that 10 of the cases 
resulted in death, and 12 in hospitalization. In addition, 16 of the 26 
cases occurred in children two years old or younger. 
FDA warns that young children may be at risk for accidental ex-
posure when fentanyl patches are discarded in trash receptacles, or 
when children find lost or improperly stored patches. Young children 
can be harmed when they place the patches in their mouths or stick 
the patches to their skin. In addition, young children are at risk of 
exposure when being held by someone wearing a partially detached 
patch that can then transfer to the child. Exposure of young children 
to a fentanyl patch can lead to serious adverse events and even death, 
due to the amount of fentanyl present in the patches. FDA stresses 
that harm can even occur with used patches because they may still 
contain a considerable amount of fentanyl. 
To prevent accidental exposure, FDA advises that patients securely 
store needed fentanyl patches out of children’s reach and sight. When 
applying a patch, FDA also recommends that patients consider cover-
ing the fentanyl patch with an adhesive film to make sure the patch 
does not come off. Finally, FDA recommends checking throughout 
the day to make sure that the patch is still in place. 
Further, FDA advises that used or unneeded patches are properly 
disposed. FDA recommends that the adhesive side of the patch should 
be folded together and then the patch should be flushed down the toilet. 
FDA notes that the agency “recognizes that there are environmental 
concerns about flushing medicines down the toilet. However, FDA 
believes that the risk associated with accidental exposure to this 
strong narcotic medicine outweighs any potential risk associated 
with disposal by flushing. When the patches are no longer needed, 
disposing by flushing completely eliminates the risk of harm to people 
in the home.” 
FDA urges health care providers to educate patients and their 
caregivers about the appropriate use and disposal of fentanyl patches. 
FDA’s consumer Web page provides detailed information for patients 
and caregivers and is available at www.fda.gov/ForConsumers/ 
ConsumerUpdates/ucm300803.htm. Providers, patients, and caregiv-
ers are also encouraged to review the fentanyl patch product label for 
instructions. The FDA safety alert is available at www.fda.gov/Drugs/
DrugSafety/ucm300747.htm. Additional consumer information about 
safe medication use and storage, and the importance of proper disposal 
of unneeded medications, is available on the AWARXE® Web site at 
www.awarerx.org/informedSiteMap.php.
Providers Asked to Advise Patients of 
Acetaminophen Safe Use Steps 
With a world of conditions and hundreds of medicines, the Acet-
aminophen Awareness Coalition asks pharmacists and other health 
care providers to educate patients and caregivers about the proper use 
of medications containing acetaminophen. As the most common drug 
ingredient in America, acetaminophen can be found in over 600 medi-
cines, including many prescription and over-the-counter medicines. 
The coalition notes that when used as directed, acetaminophen is safe 
and effective. The coalition asks providers to advise patients that there 
is a daily dosage limit for acetaminophen and that taking more than 
directed is an overdose and can lead to liver damage. 
The coalition calls on health care providers to participate in the 
Know Your Dose campaign, by reminding all patients and caregivers 
to (1) always read and follow the labels on their medicines; (2) know 
if a medicine contains acetaminophen; and (3) never take or admin-
ister two medicines that contain acetaminophen at the same time. 
Additional medication safety tips for consumers and more informa-
tion about the Know Your Dose campaign are available on the “OTC 
Medication Use” page of the AWARXE Web site at www.awarerx 
.org/OTCMedUse.php. The AWARXE consumer protection program 
and the National Association of Boards of Pharmacy® (NABP®) are 
part of the Acetaminophen Awareness Coalition.
 
Pharmacists & Technicians: 
Don't Miss Out on Valuable CPE Credit. 
Set Up Your NABP e-Profile and  
Register for CPE Monitor Today!
CPE Monitor™ integration is underway. Soon all Accreditation 
Council for Pharmacy Education (ACPE)-accredited providers will 
require you to submit your NABP e-Profile ID, assigned when you 
set up your NABP e-Profile, along with your date of birth (MMDD), 
in order to obtain continuing pharmacy education (CPE) credit for 
any ACPE-accredited activity. Many have already begun to do so.
Visit www.MyCPEmonitor.net to set up your e-Profile and register 
for CPE Monitor and avoid possible delays in your CPE reporting.
CPE Monitor is a national collaborative service from  
NABP, ACPE, and ACPE providers that will allow licensees  
to track their completed CPE credit electronically.
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Mount Prospect, IL 60056
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 ♦ Total technicians: 5,342
 ♦ Registered pharmacy support persons: 1,234
 ♦ Pharmacist-Interns: 1,547
 ♦ Total support staff: 8,123
 ♦ Iowa pharmacies: 1,510
 ♦ Nonresident (out-of-state) pharmacies: 567
 ♦ Controlled Substances Act registrants (includes pharmacies): 
16,026
 ♦ Wholesalers (in state and nonresident): 1,430
New Compliance Offi cer Territories
Effective August 1, 2012, the Board’s compliance offi cers cover 
the following areas of Iowa:
 ♦ Curt Gerhold: Benton, Cedar, Davis, Henry, Iowa, Jefferson, 
Johnson, Jones, Keokuk, Lee, Mahaska, Poweshiek, Tama, 
Van Buren, Wapello, and Washington, and the following zip 
codes in Linn County: 52213, 52314, 52214, 52404, and 52405.
 ♦ Mark Mather: Black Hawk, Bremer, Buchanan, Butler, 
Cerro Gordo, Chickasaw, Floyd, Franklin, Howard, Mitch-
ell, and Worth, and the following zip codes in Linn County: 
52233, 52302, 52401, 52402, 52403, and 52411.
 ♦ Sue Mears: Boone, Buena Vista, Cherokee, Clay, Dallas, 
Dickinson, Lyon, O’Brien, Osceola, Plymouth, Pocahontas, 
Sioux, and Webster, and the following zip codes in Polk 
County: 50111, 50131, 50265, 50266, 50309, and 50324.
 ♦ Jennifer O’Toole: Adams, Appanoose, Clarke, Decatur, 
Fremont, Jasper, Lucas, Marion, Mills, Monroe, Montgomery, 
Page, Pottawattamie, Ringgold, Taylor, Union, and Wayne, 
and the following zip codes in Polk County: 50310, 50311, 
50313, and 50315.
 ♦ Jean Rhodes: Emmet, Grundy, Hamilton, Hancock, Hardin, 
Humboldt, Kossuth, Marshall, Palo Alto, Story, Winnebago, 
and Wright, and the following zip codes in Polk County: 
50009, 50021, 50023, 50226, 50312, 50314, 50322, 50325, 
and 50327.
 ♦ Jennifer Tiffany: Adair, Audubon, Calhoun, Carroll, Cass, 
Crawford, Greene, Guthrie, Harrison, Ida, Madison, Monona, 
Sac, Shelby, Warren, and Woodbury, and the following zip 
codes in Polk County: 50316, 50317, 50320, and 50321.
 ♦ Jim Wolfe: Allamakee, Clayton, Clinton, Delaware, Des 
Moines, Dubuque, Fayette, Jackson, Louisa, Muscatine, Scott, 
and Winneshiek.
Next Board Meeting
The Board plans to hold its next meeting on November 8-9, 
2012, at the Board offi ce in Des Moines, IA. Please contact the 
Board offi ce at 515/281-5944 to confi rm.
Board Web Site
Please visit the Board’s Web site at www.state.ia.us/ibpe/. 
Board Mission
The Iowa Board of Pharmacy promotes, preserves, and protects 
the public health, safety, and welfare through the effective regula-
tion of the practice of pharmacy and the licensing of pharmacies, 
pharmacists, and others engaged in the sale, delivery, or distribu-
tion of prescription drugs and devices. Iowa Code §155A.2(1).
Follow the Board on Facebook and Twitter
 
Facebook “Iowa Board of Pharmacy”
www.facebook.com/pages/Iowa-Board-of-
Pharmacy/223126781053672
Twitter “IABoardPharmacy”
http://twitter.com/#!/IABoardPharmacy
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